- Home
- INVE vs QNCX Comparison
INVE vs QNCX Comparison
Compare INVE & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- QNCX
- Stock Information
- Founded
- INVE 1990
- QNCX 2012
- Country
- INVE United States
- QNCX United States
- Employees
- INVE N/A
- QNCX N/A
- Industry
- INVE Computer peripheral equipment
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INVE Technology
- QNCX Health Care
- Exchange
- INVE Nasdaq
- QNCX Nasdaq
- Market Cap
- INVE 87.1M
- QNCX 90.8M
- IPO Year
- INVE 1997
- QNCX 2019
- Fundamental
- Price
- INVE $3.62
- QNCX $1.60
- Analyst Decision
- INVE Strong Buy
- QNCX Strong Buy
- Analyst Count
- INVE 2
- QNCX 6
- Target Price
- INVE $5.50
- QNCX $8.00
- AVG Volume (30 Days)
- INVE 41.9K
- QNCX 124.9K
- Earning Date
- INVE 11-06-2025
- QNCX 11-12-2025
- Dividend Yield
- INVE N/A
- QNCX N/A
- EPS Growth
- INVE N/A
- QNCX N/A
- EPS
- INVE 3.12
- QNCX N/A
- Revenue
- INVE $23,538,000.00
- QNCX N/A
- Revenue This Year
- INVE N/A
- QNCX N/A
- Revenue Next Year
- INVE $9.98
- QNCX N/A
- P/E Ratio
- INVE $1.16
- QNCX N/A
- Revenue Growth
- INVE N/A
- QNCX N/A
- 52 Week Low
- INVE $2.86
- QNCX $0.69
- 52 Week High
- INVE $4.29
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- INVE 46.98
- QNCX 47.89
- Support Level
- INVE $3.73
- QNCX $1.56
- Resistance Level
- INVE $3.86
- QNCX $1.65
- Average True Range (ATR)
- INVE 0.15
- QNCX 0.08
- MACD
- INVE -0.01
- QNCX 0.00
- Stochastic Oscillator
- INVE 8.57
- QNCX 64.65
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.